New, promising approach combines metformin and SGLT2 inhibitors to treat diabetes

Helmholtz Zentrum M�nchen - German Research Center for Environmental HealthAug 4 2014

Various active substances in oral antidiabetic agents are frequently combined in the treatment of diabetes in order to achieve an effective reduction in the blood sugar. A new, very promising approach combines the substances metformin and SGLT2 inhibitors, the latter were just approved in 2012. Scientists headed by Dr. Susanne Neschen and Prof. Dr. Martin Hrabě de Angelis from the Helmholtz Zentrum M-nchen, in cooperation with Ludwig-Maximilians-Universit-t M-nchen and drug manufacturer Sanofi Aventis, have discovered how the two substances reinforce each other.

Medicinal chain reaction

SGLT2 inhibitors promote the elimination of sugar in the urine and consequently reduce the blood sugar. However, paradoxically the body reacts to this with increased sugar production in the liver. And this is where metformin comes in: it slows down the body's own sugar production. The interaction of the two substances causes a drop in blood sugar levels that is effective and prolonged, and the reduction is greater than with either substance administered on its own.

"Combination effective with minimal side effects"

"The combination of drugs effectively reduces the blood sugar, and particularly also the blood sugar peaks after meals. In diabetic mice, the double therapy produced an improvement in the long-term blood sugar level HbA1c within only two weeks," reports first author Neschen. "The duo consequently constitutes an effective treatment strategy for type 2 diabetes while also producing minimal side effects," adds Hrabě de Angelis.

Type 2 diabetes is a metabolic disorder that affects around 6 million people in Germany, and that number is steadily increasing. The Helmholtz Zentrum M-nchen focuses on developing new approaches for the prevention, diagnosis and treatment of major widespread diseases.